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Pharmacokinetics of Phenobarbital in Microenema Via Macy Catheter
Versus Suppository
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Department of Pharmacology (Y.W.F.L.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; WCCT Global
(A.L.), Cypress, California; and Hospi Corporation (B.M.), Newark, California, USAAbstract
Context. The oral route is compromised for nearly all patients approaching death. When agitation, seizures, or other
intractable symptoms occur, a quick, discreet, comfortable, and effective alternate route for medication delivery that is easy to
administer in the home setting is highly desirable.
Objectives. To characterize the early absorption profile, variability, and comfort of phenobarbital given in microenema
suspensions delivered via the Macy Catheter (MC) vs. the same dose given via suppository.
Methods. This was a randomized, open-label, crossover study comparing the early absorption profile of equal doses of
phenobarbital administered rectally in three treatment phases: phenobarbital suppository and two different microenemas
with phenobarbital tablets crushed and suspended in 6 mL (MC-6) or 20 mL (MC-20) of tap water.
Results. Mean plasma phenobarbital concentrations at 10 minutes were 12 higher for MC-20 and 8 higher for MC-6
compared to suppository. Concentrations achieved in 30 minutes via MC-20 took almost three hours to achieve with
suppository. Mean AUC values were higher for MC-20 and MC-6 (82% and 46%, respectively) vs. suppository (P < 0.05). There
was less variability in absorption for MC-20 and MC-6 (1.4- to 1.9-fold difference) compared to a 4.4-fold difference via
suppository. MC administrations were reported as ‘‘not uncomfortable’’ compared to suppositories, which were reported as
‘‘mildly uncomfortable’’ (P < 0.05).
Conclusion. These results suggest phenobarbital oral tablets crushed and suspended in water and administered via the MC
is superior to suppository in delivering the medication reliably and rapidly. J Pain Symptom Manage 2016;51:994e1001.
 2016 The Authors. Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Key Words
Rectal administration, phenobarbital, suppository, hospice care
Introduction they approach death. The ability to give phenobarbitalPhenobarbital is a commonly used medication in
hospice and palliative care. It is used for controlling
terminal agitation and seizures at the end of life and
can also be used for palliative sedation in patients
with severe intractable suffering uncontrolled by
more standard therapies. A large number of hospice
patients needing symptom control are no longer able
to take oral medications due to active symptoms or
deterioration of physical and/or cognitive function asAddress correspondence to: Y. W. Francis Lam, PharmD, FCCP,
Department of Pharmacology, University of Texas Health
Science Center at San Antonio, 7703 Floyd Curl Drive, San
Antonio, TX 78229-3900, USA. E-mail: lamf@uthscsa.edu
 2016 The Authors. Published by Elsevier Inc. on behalf of American
Academy of Hospice and Palliative Medicine. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).easily and effectively in the home setting to patients
with no viable oral route could allow them to remain
at home with symptoms well controlled, while avoiding
in-patient admissions and allowing more patients to die
in the setting of their choice. Furthermore, the ability
to rapidly control agitation and seizures in the home
setting could substantially decrease the burden of
care on the caregiver and the hospice team, improve
the quality of the death experience, and lead to anAccepted for publication: December 24, 2015.
0885-3924/$ - see front matter
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and the health care system as a whole.
The Macy Catheter (MC) is a relatively new FDA-
cleared medical device designed for rectal administra-
tion of fluids and medications. The catheter is placed
by a clinician with a procedure much like a urinary
catheter placement.1 The tip is placed just past the
rectal sphincter and a small balloon is inflated to
hold the catheter in place (Fig. 1). Medications
and/or fluids are delivered through a medication
port on the patient’s leg, allowing for repeated admin-
istrations without having to reposition the patient or
repenetrate the rectal vault. Stool in the rectum is
not a contraindication for use unless the rectal vault
is too full for insertion or the patient has diarrhea.
Solid forms of oral medications known to be absorbed
rectally can be crushed, mixed with water, and deliv-
ered in a microenema suspension or solution with
an enteral syringe. Liquid or presuspended forms of
medications are injected directly into the catheter.
The catheter is flushed with 3 mL water after the medi-
cation dose.
In a retrospective chart review conducted by Macy
et al. at a multisite home hospice agency, phenobar-
bital was administered in a microenema suspension
to 26 end-stage hospice patients with agitation and
two patients with seizures. Both agitation and seizures
were controlled quickly and effectively.2 The anec-
dotal observations were intriguing, and the investiga-
tors hypothesize that the rapid control of agitation
and seizures observed may reflect a rapid absorption
profile of phenobarbital when delivered to the rectum
in microenema form. Because rapid absorption, dose
reliability, and comfort of administration are impor-
tant factors to consider in controlling severeFig. 1. Diagrammatic representation of the Macy Catheter in
relation to the rectum.symptoms, especially in patients who have limited
time left of life, we conducted the present study to
evaluate the early absorption profile of phenobarbital
administered in microenema suspensions via MC in
comparison to a conventional suppository dosage
form, and how different fluid volume of suspensions
affects absorption profile. The primary study aim was
to evaluate the extent, rate, and variability of pheno-
barbital absorption. A secondary aim was to validate
that medication administration via the MC was
comfortable and to compare the degree of comfort
to that experienced via suppository.Methods
After providing their informed consent, 12 healthy
adult subjects were recruited for the study. The study
was approved by an institutional review board for hu-
man research (Aspire IRB, Santee, CA). All subjects
had a screening visit during which medical history,
physical examination, and standard laboratory panels
were performed to assure healthy status.
The study used a single-center, open-label, random-
ized, crossover design comparing the early absorption
profile (first 12 hours after drug administration) of
phenobarbital administered rectally via three different
methods (three treatment phases), Treatment Phases
1 and 2 consisted of drug administration via the MC
with phenobarbital 194.4 mg crushed and suspended
in 6 mL (MC-6) and 20 mL (MC-20) of tap water,
respectively. The pH of both suspensions was approx-
imately 7 per Hydrion test strip analysis. Treatment
Phase 3 consisted of 194.4 mg phenobarbital adminis-
tered via compounded suppository. Suppositories
were prepared in two batches of 100 by pulverizing
two hundred 97.2 mg phenobarbital tablets (NDC:
0603-5168) and mixing with 180 gm polyethylene gly-
col and 7.67-gm polysorbate base. The mixture was
poured into 100 molds and allowed to cool at room
temperature. The first batch was used for Study Pe-
riods 1 and 2, and the second batch for Study Period
3. For each subject, a one-month washout period sepa-
rated each study period.
Subjects spent the night in the research facility on
the evening before Study Period 1. They were admin-
istered a bisacodyl suppository to encourage bowel
movement. On the morning of the study day, subjects
randomized to receive either Treatment Phase 1 or 2
had the MC placed before phenobarbital administra-
tion. Study doses of phenobarbital were given about
30 minutes later via the MC for subjects randomized
to Treatment Phases 1 and 2, and via suppository for
subjects randomized to Treatment Phase 3.
For each subject, 10 mL of blood was obtained
through an indwelling catheter before and at 0.17,
0.33, 0.5, 0.67, 0.83, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours
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centrifuged and the harvested plasma frozen in ali-
quots at 80C for subsequent determination of
phenobarbital concentrations. In addition, the level
of discomfort with the specific mode of drug adminis-
tration was assessed with a simple subjective numeric
rating scale at the time of administration as follows:
0 ¼ not felt at all; 1 ¼ felt, but not uncomfortable;
2 ¼ a little uncomfortable but not very much;
3 ¼ uncomfortable; and 4 ¼ hurt and painful.
All subjects were discharged from the research unit
after the 12-hour blood sampling. Subjects were
required to have a driver pick them up at the facility.
After the appropriate washout time of one month,
subjects returned to receive the second and then the
third crossover drug administration according to study
randomization, in Study Periods 2 and 3, respectively.
The same study procedures and assessments were
repeated in both Study Periods as in Study Period 1.
Plasma phenobarbital concentrations were deter-
mined at the University of Texas Health Science Cen-
ter San Antonio by a validated high-performance
liquid chromatography assay. Plasma (300 mL) was
mixed with 50 mL of the internal standard phenytoin
and 5 mL of t-butyl methyl ether. The mixture was
then placed on a mechanical shaker for 15 minutes
before centrifugation at 2700 rpm for 15 minutes.
The organic layer was transferred to another tube
and evaporated to dryness under nitrogen. The resi-
due was dissolved in 300 mL of mobile phase (water:a-
cetonitrile:methanol, 59:26:15 v/v) and 25 mL was
injected onto a Symmetry C-12 column at 1 mL/min-
ute. The analytical method has a linear range of
0.5e4.0 mcg/mL with a lower detection limit of 0.1
mcg/mLThe intraday and interday CV of the low con-
trol sample was 3.8% and 3.5%, respectively; 2.8% and
3.4%, respectively for the medium control sample;
and 4.1% and 3.8%, respectively, for the high control
sample.
Because the objective of the study was to compare
the differences in extent and rate of early absorption,Table
Subjects’ Demographics and Achie
Subject Sex Age (yrs) BMI
Weight
(kg)
1 F 31 29.4 75.6
2 F 32 28.7 74.1
3 M 25 29.4 93.1
4 M 22 21.4 63.1
5 F 25 25.9 65.6
6 M 23 25.1 74.4
7 M 24 20.6 76.1
8 F 22 22.7 59.8
9 M 29 22.4 75.0
aAs measured by area-under-the plasma concentration-time curve for 12 hours after
of the study.plasma samplings were only performed for 12 hours
after drug administration. The phenobarbital area un-
der the time curve (AUC0e12) was determined by trap-
ezoidal rule. Maximal concentration (Cmax) and time
to maximal concentration (Tmax) were determined
by visual inspection of the concentration-time curves.
Differences in AUC0e12 and concentrations after
drug administration among the three different routes
were tested for statistical significance by paired Stu-
dent t-test, with 0.05 as the level of significance.Results
Seven subjects completed all three treatment phases
and two subjects completed two phases (MC-6 and
suppository only). Three subjects completed only
one treatment phase (two for the MC-6 phase and
one for the MC-20 phase). Comfort assessment, but
not pharmacokinetic analysis, was performed for these
three subjects. The demographics and AUC0e12 values
for the nine subjects completing at least two treatment
phases are summarized in Table 1. All ‘‘non-com-
pleters’’ cited the study length as the sole reason for
withdrawing from the study.
During the entire 12-hour time period, the mean
phenobarbital concentration achieved for the seven
subjects completing all three treatment phases was
consistently higher with the MC, regardless of the vol-
ume used to suspend the drug, as compared to the
suppository. In addition, the mean concentration
achieved with MC-20 was consistently higher than
with MC-6 at every sampling time point (Fig. 2).
The phenobarbital AUC0e12 (mean  SD) achieved
in these seven subjects were 82% and 46%, higher
via MC-20 and MC-6 respectively (33.1  4.3 mcg 
hr/mL and 26.6  6.2 mcg  hr/mL) than that
achieved using suppository (18.2  15.0 mcg  hr/
mL) (P < 0.05). There was also less variability in the
extent of drug absorption with the MC-20 and MC-6
administrations (1.4- to 1.9-fold difference, respec-
tively) as compared to a 4.4-fold difference with1
vable Systemic Drug Exposurea
AUC for MC-6
(mcg  hr/mL)
AUC for MC-20
(mcg  hr/mL)
AUC for
Suppository
(mcg  hr/mL)
27.6 37.3 27.8
25.7 31.6 27.4
25.6 27.2 0.0
40.0 38.4 0.0
22.8 36.3 33.7
23.4 29.5 30.7
21.4 31.7 7.6
33.0 d 18.1
29.5 d 30.5
drug administration (AUC0e12). The first seven subjects completed all phases
Fig. 2. Mean plasma concentration-time curve for seven study completers in the study.
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shows variability of phenobarbital absorption via MC-
6 (Fig. 3a) and MC-20 (Fig. 3b) administrations versusFig. 3. Variability of phenobarbital absorption profile for seven
panel) and between suppository and MC-20 (b, lower panel).suppository for all seven subjects. When data for the
two subjects who had no detectable absorption were
excluded, variability is still quite high for thestudy completers between suppository and MC-6 (a, upper
Fig. 4. Variability of phenobarbital absorption profile for five completers (excluding the two subjects with ‘‘suppository fail-
ure’’) between suppository and MC-6 (a, upper panel) and suppository and MC-20 (b, lower panel).
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(Figs. 4a and 4b).
For the two subjects that only completed the MC-6
and suppository phases, the AUC0e12 and Cmax
were 82% and 84.8% higher in one subject with
drug delivered by MC-6 (33.0 mcg  hr/mL and 3.3
mcg/mL, respectively) vs. suppository. In the other
subject, AUC0e12 and Cmax values were comparable
between MC-6 (29.5 mcg  hr/mL and 2.8 mcg/
mL, respectively) and suppository (30.5 mcg  hr/
mL and 3.1 mcg/mL, respectively).
The ranges of Cmax achieved in the seven subjects
who completed all three treatment phases were higher
with both MC administrations (2.0 to 3.8 mcg/mL for
MC-6 and 2.4 to 3.7 mcg/mL for MC-20) compared to
0.7 to 3.4 mcg/mL achieved with suppository. It is
noteworthy that two of these subjects did not achieve
measurable concentration after suppository adminis-
tration over the entire study period. In contrast, thesame two subjects achieved a Cmax of 3.7 and 2.4
mcg/mL (with MC-20), and 3.8 and 2.3 mcg/mL
(with MC-6). No absorption failures occurred for any
of the 16 MC dosing administrations analyzed for
phenobarbital pharmacokinetics.
Significant differences in rate of drug absorption
were observed in the study, being much faster for
both MC-20 and MC-6 administrations compared to
suppository. At 10 minutes after drug administration,
mean concentrations were 12 times higher for MC-20
(0.6 mcg/mL) and 8 times higher for MC-6 (0.4 mcg/
mL) compared to suppositories (0.05 mcg/mL)
(P < 0.005). Comparable mean concentrations
achieved in 30 minutes via MC-20 took almost three
hours to attain with the suppository route (Fig. 2).
In addition, absorption of 60% and 66% of the
mean Cmax, respectively, was achieved at one hour af-
ter MC-6 and MC-20 administration. In contrast, only
22% of the mean Cmax was achieved at one hour
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tory, less than half (47.6%) of the mean Cmax was ab-
sorbed at two hours after drug administration, as
compared to 83.9% and 82.6% for MC-20 and MC-6,
respectively. The rate of drug absorption was also
higher for the two subjects receiving only MC-6 and
suppository with 48% and 53% of the Cmax achieved
in both subjects at one hour after drug administration
via the MC as compared to 34% and 42.5% via
suppository.
Excluding the suppository failures in two subjects
who completed all treatment phases, the early absorp-
tion profile was still much more rapid via either MC
method of dosing (Fig. 5). Mean concentrations at
10 minutes were 5.2 higher for MC-6 and 8.4 high-
er for MC-20 vs. suppository. Mean concentration
achieved in 30 minutes with MC-20 took two hours
to achieve with suppository. Mean AUC was higher
for the MC-20 (33.3  3.4 mcg  hr/mL) but compa-
rable between MC-6 vs. suppository (24.2  2.4 mcg 
hr/mL vs. 25.4  10.3 mcg  hr/mL). The achievable
Cmax was more variable with suppository (0.7 to 3.4
mcg/mL) than with either MC-20 (2.9 to 3.4 mcg/
mL) or MC-6 (2.0 to 2.6 mcg/mL).
There were a total of 19 MC drug administrations
and nine suppository administrations performed in
the study. Data was collected on comfort of insertion
for all administrations. Based on the five-point
numeric subjective rating scale described in the sec-
tion Methods, 18 of the 19 MC insertions (95%)
were reported as ‘‘not uncomfortable’’ (Rating 1) by
the subjects. Only one subject reported ‘‘mildly un-
comfortable’’ (Rating 2). On the contrary, only three
of the nine suppository insertions (33%) were re-
ported as ‘‘not uncomfortable,’’ five reported the
insertion as ‘‘mildly uncomfortable’’ (56%), and oneFig. 5. Mean plasma concentration-time curve for five completpatient reported the insertion as ‘‘uncomfortable’’
(Rating 3). Other than the different levels of discom-
fort, there were no adverse events reported for any of
the subjects.Discussion
The rectal route of administration is a good alterna-
tive for patients when the oral route is not a viable op-
tion. It is especially beneficial in patients with
advanced illness or those at end-of-life.3 Many medica-
tions administered rectally are absorbed quickly and
effectively through the rectum. The rectal mucosa is
highly vascularized and medications delivered to the
distal third of the rectum partially avoid the first pass
effect through the liver (Fig. 1), allowing for greater
bioavailability of many medications than that achieved
with the oral route.3e6 Our study demonstrates that
phenobarbital oral tablets crushed and suspended in
water and administered via the MC is superior to sup-
pository in delivering the medication reliably, rapidly,
and comfortably.
Our data are consistent with that of Moolenaar et al.
who demonstrated that phenobarbital in both sodium
and acid forms mixed in a 20 mL aqueous microene-
ma solution consisting of 0.5% methylcellulose and
distilled water is well absorbed rectally, with practically
complete absorption at 6.5 hours after drug adminis-
tration.7 They further demonstrated that drug absorp-
tion from microenema solution was faster than from
suppositories. In another study, Graves et al.
compared rectal and intramuscular absorption of
5 mg/kg sodium phenobarbital and found no signifi-
cant difference in total AUC between the two routes of
administration.8ers (excluding the two subjects with ‘‘suppository failure’’).
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readily available oral forms of medications could
have practical importance in keeping patients
comfortable at home, while decreasing the burden
of care on caregivers and the health care system as a
whole. This is the first study to evaluate the early ab-
sorption profile, reliability of dose delivery, and com-
fort of administration of phenobarbital oral tablets
given in microenema form with the MC, a pragmatic
and easy method of administering medications that
could be easily used by a caregiver in the home setting.
Drug absorption from suppository can be variable
depending on the method of preparation and the
presence of stool in the rectal vault.5 Based on anec-
dotal experience, a suppository, if actually placed in
a mass of stool, may provide minimal medication
bioavailability. Two of nine subjects (22%) in our study
who received suppositories had no detectable pheno-
barbital concentrations at any point after administra-
tion. It is not known why these suppositories failed
to be absorbed. All suppositories were prepared the
same way for the study, so it is unlikely that it was a
dose uniformity issue or preparation failure. One pos-
sibility could be suppository placement near or in a
mass of stool.
It is noteworthy to mention that there were no ab-
sorption failures for any of the 16 MC-delivered doses
that had pharmacokinetic analysis in this study. All
MC-delivered doses achieved a Cmax of at least 2
mcg/mL, compared with suppositories in which two
subjects had no drug absorption, and one only
achieved a relatively low Cmax of 0.71 mcg/mL.
Medications administered as aqueous liquid formu-
lations are generally absorbed more quickly than the
same medication administered via suppository.4,9
Another possible reason contributing to absorption
failure from suppository in two study subjects, and
low Cmax of 0.7 mcg/mL in the third subject, could
be due to limited fluid volume in the rectum resulting
in inadequate dissolution of the medication. In this
study, increasing the amount of water to suspend
phenobarbital resulted in a faster and better absorp-
tion profile, and decreased dose variability. For the
seven subjects who completed all three treatment
phases, mean phenobarbital concentrations at 10 mi-
nutes were 12 times higher for MC-20 (0.6 mcg/mL)
and 8 times higher for MC-6 (0.4 mcg/mL) compared
to suppositories (0.05 mcg/mL). Phenobarbital
administered via suppository took eight hours to
attain concentrations achieved in one hour via MC-
20 and 1.5 hours via MC-6. The extent of absorption
as measured by AUC0e12 were 82% and 46% higher
with MC-20 and MC-6, respectively, than with supposi-
tory. Variability in extent of absorption was also corre-
lated with the amount of water used to suspend
phenobarbital, with a 1.4-fold difference amongsubjects for the MC-20, a 1.9-fold difference for the
MC-6, and a 4.4-fold difference for the suppository.
Based on our findings, the suppository could not be
recommended for rapid and reliable absorption of
medication. The differences in rate and extent of ab-
sorption could be clinically significant when quick
and effective control of symptoms is needed, as termi-
nal patients are many times quite dehydrated making
absorption of medication from suppository even more
challenging. If absorption is delayed significantly via
suppository, degradation of the medication could
occur by bacterial metabolism, decreasing the overall
bioavailability of the drug.3
Caregivers are many times reluctant to use supposi-
tories due to invasion of privacy and embarrassment is-
sues. Suppositories can also be physically
uncomfortable when administered as demonstrated
in this study. Based on a 0 to 4 rating scale, subjects as-
sessed administration of phenobarbital via supposi-
tories to be ‘‘mildly uncomfortable’’ (mean ¼ 1.77)
compared to administration via the MC as ‘‘not un-
comfortable’’ (mean ¼ 1.0) (P < 0.05). Although
mild discomfort may be considered an acceptable
tradeoff when treating active severe symptoms,
repeated uncomfortable procedures could disturb or
awaken calm patients and escalate agitated or painful
states, negating symptom control efforts. In addition,
suppository administration involves repositioning of
the patient with each dosing, which could be painful
and agitating for a patient and difficult for elderly or
disabled caregivers.
A primary limitation of our study is related to gener-
alizability of the findings from healthy young volun-
teers to a very ill and generally older patient
population. Further research is needed to better
define the potential role of microenema-delivered
medications via the MC. Determination of the optimal
volume for suspending medications should be further
studied. Characterization of the absorption kinetics of
frequently used palliative drugs that have not been
well studied rectally, such as haloperidol and dexa-
methasone,3,4,6,10 will assist clinicians in developing a
formulary for palliative medications that can be given
effectively in microenema form. Clinical assessment of
symptom control and tolerability of the MC, as well as
ease and acceptability of use in the home and inpa-
tient hospice settings would be beneficial. Studies on
the effectiveness of the MC as a tool to facilitate
discharge from higher acuity settings or avoid admis-
sion into these settings would further our understand-
ing of the role of the MC in end-of-life care.Conclusion
The absorption kinetics of MC-administered pheno-
barbital microenemas were superior to compounded
Vol. 51 No. 6 June 2016 1001Rectal Drug Administration in the Hospice Settingphenobarbital suppositories, including rate of early
absorption, overall absorption, variability, and comfort
of administration. Based on these findings, the use of
compounded phenobarbital suppositories may pro-
duce unreliable and delayed results for managing
agitation, seizures, or intractable suffering. Further-
more, based on our findings of the correlation be-
tween increased fluid and increased absorption/
decreased variability, the practice of inserting solid
tablets directly into the rectum without dispersing
them in water may provide even worse results than
that of suppositories. On the other hand, the adminis-
tration of microenemas with a rectal access device
such as the MC could play an important role in the
rapid control of symptoms related to agitation, sei-
zures, and intractable suffering in the home setting, al-
lowing more patients to die peacefully in the
environment of their choice.Disclosures and Acknowledgments
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